Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients

Abstract

Aims In renal allograft recipients, trimetazidine (Vastarel^® ) was proposed to be associated with the classic immunosuppressant treatments because it displays anti-ischaemic effects which may protect against cyclosporine A nephrotoxicity. The objective of this work was to assess the possibility of coadministering cyclosporin A, Sandimmun^®, and trimetazidine.

Methods Twelve renal transplant patients were selected on the basis of the stability of their cyclosporine A blood concentrations for the previous 3 months. They received trimetazidine, 40 mg twice daily orally for 5 days. Other coadministered drugs were kept unchanged during the study. Before and after trimetazidine administration, cyclosporine A blood concentrations, plasma interleukin-2 and soluble interleukin-2 receptor levels were measured.

Results The data showed that neither cyclosporin A blood pharmacokinetic parameters, C_max, t_max, AUC, nor the concentrations of interleukin-2 and soluble interleukin-2 receptors were significantly modified.

Conclusions Therefore, it was suggested that trimetazidine may be coadministered with cyclosporine A without cyclosporine A dosage adjustment.

Full Text

The Full Text of this article is available as a PDF (99.4 KB).